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Predictive value of renal pathology in diffuse proliferative lupus gb-
merulonephritis. We tested the value of the activity (A!) and chronicity
(CI) indices devised by Austin et alE!, 21 as predictors of outcome in
lupus patients with diffuse proliferative glomerulonephntis (DPGN).
Four renal pathologists independently scored the Al and CI on 84 renal
biopsy specimens from patients with lupus DPGN followed for 109 74
weeks (mean SD), and the mean score was compared to the
development of renal failure and to adverse outcome (combined data for
renal failure, death and predefined clinical stop points). Receiver
operator characteristic curves were derived from a series of 2 x 2 tables
in which one variable was renal failure or adverse outcome and the
other variable was Al or Cl dichotomized by a cut-off point. Over the
entire range (0 to 10) of the CI there was no value that separated
patients who developed renal failure from those who did not. The ROC
curve analysis indicated that the sensitivity and specificity of the CI
were too low to allow it to function as a good test. Once patients
entering renal failure were identified, the mean CI approached but did
not reach a significant difference when compared to the mean CI of
those who did not go into renal failure (4,38 0.42, mean SE vs. 3.19
0.23, P = 0.0620). The Cl did not predict the adverse clinical
outcomes, There was no cut-off value of the CI which separated
patients who had an adverse outcome from those who did not, and this
result was confirmed by ROC analysis. As a group, the patients who
reached an adverse outcome had a higher CI (4.12 0.37, mean SE)
than those who did not (3.2 0.24), but this difference was not
significant (P = 0.3944). In this population of patients with the his-
tologic diagnosis of DPGN, there was no value for the Al over its entire
range (4 to 22) that predicted either renal failure or adverse outcome.
The mean Al was not different either for those who developed renal
failure and those who did not (11.24 0.48, mean SE vs. 11.35 0.47,P = 0.7257) or for those with and without an adverse outcome (11.41
0.44, mean SE vs. 11.27 0.50, P = 0.7061). This finding indicates
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that the degree of inflammation required for the diagnosis of DPON is
alone predictive of outcome. Since the histological indices did not
improve the predictive value of the standard histological classification
(ISKDC/WHO) in this group of patients with DPGN, we recommend
holding in abeyance therapeutic decisions based upon the CI until its
predictive value is independently confirmed.
Glomerular pathology has been demonstrated to be an indi-
cator of prognosis in the patient with systemic lupus erythema-
tosus (SLE) [2—7]. Although patients falling within the category
of diffuse proliferative glomerulonephritis (DPGN) have the
worst prognosis among those with lupus nephritis, there is
marked variability in the clinical course. Because of this, efforts
have been made to define the histological features associated
with a poor renal prognosis. Austin et al [1, 2] have reported
that a semiquantitative index of glomerular sclerosis, fibrous
glomerular crescents, tubular atrophy, and interstitial fibrosis
(Chronicity Index, CI) is a better indicator of renal failure than
is either a conventional histological classification system based
upon the extent and nature of the glomerular abnormality or an
index based upon the quantitation of active histological signs of
acute inflammation (Activity Index, Al). Because of the broad
prognostic and therapeutic implications of these studies, others
[8, 9] have attempted to duplicate their findings with conflicting
results.
As part of a multicenter, prospective, randomized trial of the
effect of plasmapheresis on outcome in severe SLE glomerulo-
nephntis (GN), we have biopsied and studied a large number of
patients with histologic diagnosis of DPGN as defined by the
International Study of Kidney Disease in Children/World
Health Organization (ISKDC/WHO) Classification [10]. To test
the efficacy of the Al/Cl as predictors of outcome in patients
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Number of patients
Age
Male/female
Caucasian
Black
Hispanic
Other
Renal involvement to biopsy
Diastolic blood pressure
Serum creatinine
Serum C3
Urine protein excretion
Azathioprine within
3 months of biopsy
Alkylating agent within
3 months of biopsy
Prednisone therapy at time
of biopsy
a Mean SD
with SLE and DPGN, we scored each biopsy for activity and
chronicity indices, and the histological indices were related to
outcome.
Methods
Patients
The present analysis is based upon the 84 patients from whom
prerandornization renal biopsy specimens were available in the
Study of Plasmapheresis In Severe Lupus Nephritis undertaken
by the Lupus Nephritis Collaborative Study Group (LNCSG).
The detailed pathologic description of the biopsies [11] has been
reported elsewhere, The patients' clinical and laboratory values
are given in Table 1. Admission criteria included: (a) a diagnosis
of SLE conforming to the criteria of the American Rheumatism
Association [14]; (b) clinical evidence of' renal disease; (c) the
absence of defined exclusion criteria (Table 2); and (d) biopsy
diagnosis of DPGN obtained within three weeks of randomiza-
tion. The 85 patients who met the admission criteria were
randomized to either standard treatment or standard treatment
plus plasmapheresis to assess the clinical effect of plasmapher-
esis in severe lupus GN. All patients received 60 mg/day
prednisone if they weighed less than 80 kg and 80 mg/day if they
weighed more than 80 kg. They received this dose for four
weeks, after which they were reevaluated and either continued
or entered into a regimen with tapering dosage. They also
received cyclophosphamide, 2 mg/kg/day, for five weeks, fol-
lowed by 1 mg/kg/day for 2 weeks. Cyclophosphamide was then
discontinued [12]. The validity of the therapeutic trial depended
upon the homogeneity of the patients in the different treatment
groups. A total of 45 demographic features, historical and
therapeutic details, physical findings, and laboratory data were
compared for the standard and the standard plus plasmaphere-
sis groups, and they were similar in all respects [11]. The ARA
criteria gave us a standard for the diagnosis of systemic lupus
erythematosus; the exclusion criteria assured us that the pa-
tients were able to tolerate either therapeutic regimen and that
they did not have end-stage kidney disease; the renal biopsy
documented the presence of "active" inflammation and/or
necrosis in fifty percent or more of the glomeruli. Thus, the
patients were homogeneous with respect to the severity of their
Table 2. Exclusion critera
A. Less than 16 years old.
B. Currently pregnant.
C. Serum creatinine greater than 6 mg/dl.
D. Ever received plasmapheresis.
E. Has a history of primary myocardial disease.
F. Has a history of neoplasia within past 5 years.
G. Has a history of prednisone associated psychosis.
H. Has a history of peptic ulceration documental by radiology or
endoscopy within the past 3 years.
I. Has evidence of primary active liver disease.
J. Physician does not agree to patient participating in the study.
renal lesions, the type and severity of systemic symptoms, and
the therapy they received. The two treatment groups did not
differ with respect to the prognosis of severe SLE GN, survival,
development of renal failure, or the appearance or outcome of
severe life-threatening complications [13]. Study entry and
analysis began at the time of randomization, and the length of
follow-up ranged from 3 to 258 weeks with a mean of 109 74
weeks (mean SD).
Renal pathology
Pathology material. The Central Pathology Laboratory re-
ceived the following materials from the individual clinic pathol-
ogists: (1) the set of histologic slides stained with hematoxylin
and eosin, Masson's trichrome, periodic acid-Schiff (PAS), and
PAS-silver methenamine that had been used in the clinic to
establish the histologic diagnosis and to determine eligibility; (2)
photomicrographs documenting immunofluorescence staining
with anti-IgG and anti-fibrin; and (3) copies of the electron
micrographs. Methodological details have been previously re-
ported [13]. The morphological material was coded in the
Central Pathology Laboratory so the pathologists scoring the
biopsies would not have direct knowledge of the clinic labora-
tories or of their pathologic diagnosis.
Definition of DPGN as an entry criterion. The biopsies were
classified according to a modification of the ISKDC/WHO
classification of SLE ON [10]. DPGN, as described in the
literature [3—7], includes a heterogenous group of lesions that
are separated from less severe forms of lupus ON by signs of
"severe" inflammation in the majority of the glomeruli. For the
purpose of this report the diagnosis of DPGN was established
either by: (1) involvement of all or nearly all (more than 80%) of
glomeruli by severe cellular proliferation and infiltration in a
global endocapillary, mesangiocapillary or crescentic pattern or
by prominent subendothelial deposits; or (2) severe segmental
UN with active histological evidence of inflammation in more
than 50% of the glomeruli [7, 15]. Patients with extensive
epimembranous immune deposits who also had severe prolifer-
ative changes in more than 50% of glomeruli qualified to enter
this study. These forms of lupus GN are the most severe end of
the morphologic spectrum of the ISKDC/WHO categories. A
minimum of ten glomeruli were required for classification, and
the 84 biopsies contained 19.4 10 glomeruli (mean SD).
One-third of the biopsies had no hyalinized glomeruli, and those
with obscolescent glomeruli had 2.9 0.6 glomeruli (mean
SD) involved.
Activity and chronicity indices (Al/Cl). The published criteria
for scoring the Al/Cl were followed [1, 2]. The following
Table 1. Patient characteristics at baseline
84
32.1 12.5 yearsa
14/70
60%
22%
7%
11%
13.40 27.22 monthsa
88 13 mm Hga
2 1.30 mg/dla
57 29 mgldla
5.5 4.2 g/24 hoursa
13%
7%
75%
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features were scored on the basis of the percentage of total
glomeruli involved (less than 25 percent—i +, 25 to 50 per-
cent—2+, and >50 percent—3 +): glomerular cell proliferation,
karyorrhexis and fibrinoid necrosis, cellular crescents, hyaline
deposits (wire loops and hyaline thrombi), glomerular sclerosis,
and fibrous crescents. Leukocyte exudation was scored on the
number of neutrophils/glomerulus, (2/glomerulus—i +, 3/gb-
merulus—2 +, 3 or more/glornerulus—3 +). Interstitial inflam-
mation, tubular atrophy, and interstitial fibrosis were scored as
mild (<20 percent—l+), moderate (20 to 40%) or severe
(>40%) based on the proportion of cortical tissue involved. The
Al/Cl were the sum of the scores of the individual pathological
featLres except for karyorrhexis/fibrinoid necrosis and cellular
crescents which were weighted (score x 2). The Al was thus
defined as the sum of the scores for glomerular proliferation,
leukocyte exudation, karyorrhexis and fibrinoid necrosis (x2),
cellular crescents (x2), hyaline deposits and interstitial inflam-
mation. The maximum score for the AT was 24 points. The CI
was the sum of glomerular sclerosis, fibrous crescents, tubular
atrophy, and interstitial fibrosis. The maximum score for the CI
was 12 points.
Pathology Reading Committee (PRC)
The eligibility of the patient for entry into the study, based on
the renal pathology, was determined by the individual clinic
pathologists, but histologic stratification and scoring of the A!
and CI were accomplished by the PRC. As cases accrued, the
PRC met at six month intervals and reached a consensus on
histologic diagnosis and patient eligibility in each case after
examining all the pathology materials and filling out a detailed
worksheet. The worksheet was sent to the LNCSG Biostatisti-
cal Coordinating Center (BCC) in Bethesda, Maryland for
analysis. At the end of the Clinical Trial, the Chairman of the
PRC (MMS) abstracted the criteria for the Al and CI, and, after
consultation with the other members, a second worksheet was
constructed. Each member independently scored each biopsy
for Al and CI. The worksheets containing each member's score
for the Al and C! were sent to the BCC for analysis. Evaluation
of Al/Cl in relation to outcome and pathologic diagnosis are
based upon the mean score of the four observers.
Outcomes
Three endpoints were organized in the clinical trial: death
(due to renal and non-renal causes), chronic renal failure (serum
creatinine 6.0 mgldl or a rise in serum creatinine of >3.0
mg/dl), or defined clinical stop points that indicated serious
complications due to SLE, the therapeutic program or an
intercurrent disease process [12]. For this presentation only
renal failure and adverse outcome, the latter comprising all
three study endpoints, will be analyzed in relationship to the CI
and the A!.
Statistics
Sensitivity and specificity were determined from a series of 2
x 2 tables in which the binary outcome variable (renal failure/
no renal failure; adverse outcome/no adverse outcome) is one
classification and activity or chronicity dichotomized by a
cutoff point is the second classification. In this type of analysis
the 2 x 2 tables for each value of the test (CI or Al) allows the
calculation of a chi-square statistic [16]. When the specificity
Table 3. Chronicity index (CI) summarized by outcomes (Austin et
al [2] definition of chronicity cut offs)
Present
N
Not present
N
Totals
N
Renal failureaCIl 2a 11 13
CI=2,3 5 24 29CI4 16 26T 424
= 4.86
Adverse outcomeCI1 2 11 13
CI=2,3 8 21 29CI4 18
-
24 424
x2 = 403b
a Defined in text
b None of the above statistics reach the 5% significance level, the
critical values for the chi-square distribution being 5.99 for 2 degrees of
freedom (chronicity).
and sensitivity of each test value are plotted (ordinate =
sensitivity and abscissa = 1— specificity), the resulting receiver
operator characteristics (ROC) curve describes the diagnostic
efficacy of the test [17, 181. For example, in a test that has both
high sensitivity and specificity the ROC curve will be shifted up
and to the left. The point where the rapidly rising curve shifts to
a plateau will be the value separating the true positives from the
true negatives. In contrast a curve with low sensitivity and
specificity will be a straight line midway between the axes. For
each outcome, a Wilcoxon Rank Sum Test was carried out for
both Activity and Chronicity, within each Pathology Category.
The tests, appropriately weighted, were combined over these
strata and (applying the normal approximation) yielded P-
values quoted in the text [19].
Results
Relationship of the CI to the specific outcome of renal failure
The CI did not predict renal failure as a specific outcome. The
entire range (range = 0 to 10) of CI scores was evaluated for
predictive efficacy, and there was no value of the CI that
separated patients who developed renal failure from those who
did not develop renal failure (data not shown). For example,
when the cutoff points, previously reported to have graded
predictive values, were tested [2] (Table 3), they failed to
separate patients with and without renal failure. The same data
were used in the ROC analysis (Fig. 1), and the data revealed a
straight line relationship. That is, for any value of the CI the
patient had a 50% chance of reaching the renal failure endpoint,
and as a test, the C! did not predict the occurrence of renal
failure for individuals. While not prospectively predictive, the
mean CI of patients who developed renal failure was higher
than those who did not reach renal failure, but this analysis of
retrospective difference did not reach statistical significance
(4.38 0.42, mean SE vs. 3.19 0.23, P = 0.0620).
Relationship of the CI to the combined study outcomes
The CI was tested against the combined study outcomes
(death, renal failure, and clinical stop points), and it did not
predict an adverse result. There was no value of the CI which
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0.6
>
Cl,C
(0 0.4
separated patients who reached an adverse outcome from those
who did not (data not shown), and the selected values of the CI
[2] illustrated in Table 3 did not reach significance. The ROC
analysis based upon these data (Fig. 2) graphically demon-
strates the predictive failure of the CI. As a group, the patients
who reached an adverse outcome had a higher CI (4.12 0.37,
mean SE) than those who did not reach an adverse outcome
(3.2 0.24), but the difference was not significant (P = 0.14).
Relationship of the Al to the spec j/ic outcome of renal failure
and to the combined study endpoints (adverse outcome)
There was no predictive value for the Al over its entire range
(range 4 to 22). When the patients were arbitrarily divided at a
score of 12 (12 < Al  12) [2], there was no predictive value for
either renal failure or adverse outcome (Table 4). When the data
in the 2 X 2 tables was used to determine specificity and
sensitivity, ROC curves for renal failure (not shown) and
adverse outcome (Fig. 3) were straight lines. Thus, the Al did
not predict renal failure or adverse outcome in our individual
patients with DPGN. When the mean AT for the group of
patients who developed renal failure (11.24 0.48) was com-
pared with the mean AT for the group of patients who did not
develop renal failure (11.35 0.47), there was no difference (P
= 0.7257). The mean Al was also tested for all the study
endpoints, and there was no difference between the group with
adverse outcome (11.41 0.44, mean SE) and without
adverse outcome (11.27 0.50, P = 0.385).
Discussion
The glomerular lesion of DPGN has been considered to carry
a poor prognosis in lupus patients [2—7, 15], and it appears to
reflect a degree of systemic disease activity that places the
patient at increased risk of both renal and non-renal complica-
tions of SLE [2—7, 15]. In this study of a clinically well-defined
group of patients with lupus DPGN who had been treated
according to defined therapeutic protocols, neither the Al nor
*
a
1.0
0.8
0.6
>
1C
0.4
0.2
0.0
a
Table 4. Activity index
[21
(Al) summarized by outcomes
definition of activity cut offs)
(Austin et al
Present Not present Totals
N N N
Renal failurea
AI<12 iia 30 41
AI12 12 31T 43
= 0.0I2
Adverse outcomea
AI<12 13 28 41
AI12 15 28 43
=
1.0
0.8
*
*
0.8
*
0.0 0.2 0.4 0.6 0.8 1.0 a Defined in textb None of the above statistics reach the 5% significance level, the
1 - Specificity critical values for the chi-square distribution being 3.84 for 1 degree of
Fig. 1. ROC curve using CI as a test for renal failure. The curve freedom (activity).
indicates that CI does not differentiate patients who develop renal
failure from those who do not.
1.0
*
*
0.6 *
*
a,C0.4 *
0.2
—'
0.0
1.0 0.0 0.2 0.4 0.6 0.8 1.0
Fig. 3. ROC curve using Al as a test for the study endpoints (renal
failure, death and clinical stop points). The curve indicates that the Al
does not distinguish patients who reach a study endpoint (adverse
outcome) from those who do not.
0.2 *
0.0
0.0 0.2 0.4 0.6 0.8
1 - Soecificity
Fig. 2. ROC curve using CI as a test for the study endpoints (renal
failure, death and clinical stop points). The curve indicates that CI does
not distinguish patients who reach a study endpoint (adverse outcome)
from those who do not.
*
*
1 - Specificity
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the CI identified the individuals who would develop adverse
outcomes or renal failure over a mean follow-up of 109 74
(mean SD) weeks. There were no significant differences in the
CI between groups of patients who did well and those who did
poorly, and the lack of a discriminating value for either the Al
or the CI markedly reduces their prognostic value in individual
patients. Thus, the histological indices of glomerular injury
proposed by Austin et all 1, 2] failed to augment information
available from standard histopathologic evaluation.
Patients with an elevated CI, analyzed as a group, may be at
greater risk of developing renal failure than individuals with
comparable "active" glomerular lesions and no morphological
evidence of chronicity. Austin et al reported that an elevated CI
identifies a group of patients at risk of developing renal failure
when they are followed for four [1] and five [2] years. Rush et
al [8] studied 20 children with diffuse proliferative lupus GN.
Using an index of clinical outcome based on urinalysis, serum
creatinine, need for dialysis/transplantation, and death from
end-stage renal failure, they found that CI was predictive of
renal outcome but the A! was not. However, the significance of
these observations may be questioned. The presence of both an
elevated CI and DPGN in a renal biopsy implies not only
irreversible damage but the potential of further glomerular
destruction and loss of renal function. It is logical to reason that
a patient with lupus nephritis who has travelled a portion of the
road to renal failure will develop renal insufficiency more
quickly than a patient with comparable glomerular inflammation
who has not yet suffered irreversible nephron loss. The problem
with this tautological approach is that most patients with an
elevated CI do not develop renal failure (Table 3). In fact, an
elevated CI did not help us to identify the individual patient who
developed renal failure after a mean follow-up of 109 weeks.
The reason that some patients with an elevated CI eventually
develop renal failure may be related to non-immunological
factors in the progression of chronic renal disease. A less
speculative interpretation of the data, based upon our current
understanding of the pathogenesis of glomerular scarring and
nephron loss in lupus nephritis, is that patients with an elevated
CI exhibit the sequelae of a protracted course and have a more
advanced renal lesion at the time of biopsy.
The pathology seen on renal biopsy is frequently used as a
therapeutic guide in addition to its role as a prognostic indicator
[2, 7, 15]. The effectiveness of standard treatment and the lack
of correlation between the activity index and outcome is
attributed, at least in part, to the response to therapy of the
"active" signs of inflammation that form the basis for the
ISKDC/WHO classification [20]. In contrast, Magil et al [9]
found that the AT but not the CI predicted renal insufficiency
(established Se,. = 2.0 mg/dl). General experience with lupus
nephritis dating from the first renal biopsy study [3] indicates
that patients with DPGN should be treated whether or not the
glomerular lesion is accompanied by chronic parenchymal
damage. The CI indicates a level of chronic renal damage, and
the glomerular scars, tubular atrophy and interstitial fibrosis
that constitute the CI are thought to be irreversible and thera-
peutically unresponsive. In drawing a distinction between
chronic parenchymal damage and glomerular "activity," the CI
has focused attention on untreatable abnormalities. The rational
therapy of lupus nephritis is directed at reducing the destructive
effect of the active inflammatory lesion, and any implication
that the CI is an independent therapeutic guide should be
discouraged.
Technical issues regarding accurate quantitation and repro-
ducibility of a histologic index must be taken into consideration
if we are to evaluate the potential benefit of this parameter.
Histopathologic grading systems, such as the activity and
chronicity indices, are based upon a series of subjective inter-
pretations. Differences among pathologists or between tempo-
rally separate observations by a single pathologist are fre-
quently a function of observer variation rather than real
differences in pathology [21—23]. Even assuming that the his-
tologic indices are reproducible, a minor amount of chronic
disease may significantly elevate the CI. Glomerular sclerosis
involving less than 25% of the glomeruli and concomitant
tubular atrophy and interstitial fibrosis can result in the calcu-
lation of a CI of 2 or higher, and Austin et al report that patients
with even this level of chronicity had a significantly worse
course than those with a CI of I or 0. However, analysis of their
published reports [1, 2] reveals 30 patients who did not develop
renal failure who had glomerular lesions other than DPGN and
a chronicity index of two or higher [24]. If the chronicity index
only predicts renal failure in patients with DPGN, its usefulness
is considerably diminished in lupus, a disease with notorious
variability in its rate of progression and a significant proportion
of initially benign forms of glomerulonephritis that transform to
more aggressive lesions. The issues raised by Austin et al [1, 2,
25, 26] in the histologic assessment of the renal biopsy in lupus
are important. However, the lack of predictive value of the CI
in our large group of patients with DPGN and in lupus patients
with glomerular lesions other than DPGN raises doubt regard-
ing the clinical value of this measurement. We recommend
holding in abeyance therapeutic decisions based upon the CI
until its value is independently confirmed.
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